达托霉素联合磷霉素对比达托霉素单药治疗MRSA菌血症和心内膜炎:随机临床试验
在18家西班牙医院开展的一项随机、开放标签、平行组3期优越性临床试验,纳入成人MRSA菌血症住院患者,比较达托霉素联合磷霉素与达托霉素单药的疗效。联合组微生物学失败和复杂性菌血症更低,但导致停药的不良事件更多。
要点
- 联合组治疗成功率54.1% vs 单药组42.0%,差异未达统计学显著。
核心结论
- 达托霉素联合磷霉素较达托霉素单药提高12%治疗成功率,但差异未达统计学显著。
- 联合方案减少微生物学失败和复杂性菌血症,但不良事件导致停药更常见。
研究设计与样本
- 随机(1:1)、3期优越性、开放标签、平行组临床试验,在18家西班牙医院开展。
- 纳入成人MRSA菌血症住院患者,随机接受达托霉素10 mg/kg每日静脉联合磷霉素2 g每6小时静脉,或达托霉素10 mg/kg每日静脉。
- 167例随机,155例完成试验并纳入主要终点评估。
- 主要终点为治疗结束后6周的治疗成功。
临床怎么用
- 对MRSA菌血症和心内膜炎,达托霉素联合磷霉素可减少微生物学失败和复杂性菌血症。
- 联合方案不良事件导致停药风险较高,需权衡获益与耐受性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. METHODS: A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy. RESULTS: Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93-1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018). CONCLUSIONS: Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events. CLINICAL TRIALS REGISTRATION: NCT01898338.
引用
- Pujol M, Miró JM, Shaw E, et al. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin Infect Dis. 2021. PMID: 32725216. doi:10.1093/cid/ciaa1081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。